Equities

Anpario PLC

Anpario PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)312.50
  • Today's Change0.00 / 0.00%
  • Shares traded20.75k
  • 1 Year change+27.55%
  • Beta1.0088
Data delayed at least 20 minutes, as of Sep 20 2024 16:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Anpario PLC's revenues fell -6.36% from 33.10m to 31.00m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 3.30m to 2.53m, a -23.46% decrease.
Gross margin46.85%
Net profit margin9.23%
Operating margin10.00%
Return on assets6.70%
Return on equity7.69%
Return on investment7.28%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at Anpario PLC fell by 1.20m. However, the company earned 8.70m from its operations for a Cash Flow Margin of 28.05%. In addition the company generated 1.21m cash from investing, though they paid out 10.96m more in financing than they received.
Cash flow per share0.2523
Price/Cash flow per share14.97
Book value per share1.75
Tangible book value per share1.23
More ▼

Balance sheet in GBPView more

Anpario PLC has little financial risk as the capital structure does not rely on leverage.
Current ratio6.15
Quick ratio4.84
Total debt/total equity0.0021
Total debt/total capital0.0021
More ▼

Growth rates in GBP

Year on year, growth in dividends per share increased 1.90% while earnings per share excluding extraordinary items fell by -10.90%. The positive trend in dividend payments is noteworthy since very few companies in the Crops industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg)2.42%
Div growth rate (5 year)8.25%
Payout ratio (TTM)41.49%
EPS growth(5 years)-6.20
EPS (TTM) vs
TTM 1 year ago
58.28
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.